Eli Lilly and Company has entered into a definitive agreement to acquire Ventyx Biosciences, a San Diego-based clinical-stage biopharmaceutical company focused on developing oral therapies for inflammatory-mediated diseases.
The acquisition by Lilly aims to strengthen its capabilities in addressing chronic inflammation and expanding its pipeline of small molecule therapeutics.
Pipeline Expansion
Ventyx's clinical pipeline includes small molecules for oral therapies targeting chronic inflammation across various disease states.
Strategic Partnership
The acquisition enhances Lilly's ability to offer innovative solutions for patients with inflammatory-mediated diseases through NLRP3 inhibitors.
Financial Details
Lilly will acquire Ventyx for $14.00 per share in an all-cash transaction, with an aggregate equity value of approximately $1.2 billion.
- The acquisition allows Lilly to tap into Ventyx's expertise in developing NLRP3 inhibitors for improved treatment of chronic inflammation.
- It positions Lilly to address a broader range of disease states with high unmet needs related to inflammation, including cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders.
The acquisition of Ventyx Biosciences aligns with Lilly's commitment to advancing novel therapies for challenging diseases. It represents a strategic move to enhance Lilly's offerings in the field of inflammatory-mediated diseases.